Posters & publications
TITLE
DOWNLOAD
Foundation Fighting Blindness 2025 Presentation: Advancing PRPF31 Related Retinitis Pigmentosa Treatment: Key Insights from the VP-001 Phase 1B Study
RANZCO 2024 presentation: a Phase 1 first-in-human study of VP-001 designed to treat retinitis pigmentosa type 11
ARVO 2024 presentation: a peptide conjugated oligonucleotide for the treatment of retinitis pigmentosa type 11
VP-001 as an interventional therapy for patients with PRPF31 mutation-associated retinal dystrophy
RNA therapeutics in the treatment of retinal disease: delivering the potential
Enhancement of antisense oligomer cell penetration in retinal layers using a modular cell penetrating peptide platform
Modulation of CNOT3 expression using antisense oligomers to treat retinitis pigmentosa type 11
GFP-complementation assay to detect functional CPP and protein delivery into living cells
Exploring microperimetry and autofluorescence endpoints for monitoring disease progression in PRPF31-associated retinopathy
PYC-001, a peptide-conjugated phosophorodiamidate morpholino oligomer for the treatment of autosomal dominant optic atrophy